This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements contain words such as "may," "will," "might," "expect,"
"believe," "anticipate," "could," "would," "estimate," "continue,"
"pursue," or the negative thereof or comparable terminology, and may
include without limitation information regarding the company's
expectations, goals or intentions regarding the future, including without
limitation statements regarding the company's anticipated recurring revenue
growth (and that such growth will support future growth and earnings
goals), expectations on earnings growth (and that such growth will be in
line with the company's objectives), potential or planned investment in
future growth vehicles, the full year outlook for the company's tax rate,
earnings and per share objectives, heavy instrument placements relative to
the company's future growth potential, growth outside the United States
(and that such growth will support the company's long-term growth
prospects), timing for the launch of the company's next generation
hematology system, the company's expectations on expanding its installed
base, and that the company's products in the Flow Cytometry market are
industry-leading and have an unparalleled range, and statements under the
heading "Full Year
|SOURCE Beckman Coulter, Inc.|
Copyright©2008 PR Newswire.
All rights reserved